Zhang Y, Guo J, Chen W, Zhao L, Huang X. Risk factors, treatments and outcomes of patients with light chain amyloidosis who relapse after autologous stem cell transplantation. Bone Marrow Transplant. 2023 Dec 26. https://doi.org/10.1038/s41409-023-02185-z.

Bianchi G, Kumar S. Systemic amyloidosis due to clonal plasma cell diseases. Hematol Oncol Clin North Am. 2020;34:1009–26. https://doi.org/10.1016/j.hoc.2020.08.001.

Article  PubMed  Google Scholar 

Administration U.S.F.D. FDA Grants Accelerated Approval to Darzalex Faspro for Newly Diagnosed Light Chain Amyloidosis. [(accessed on 15 January 2021)]. https://www.fda.gov/drugs/drug-approvals-and-databases/fda-grants-accelerated-approval-darzalex-faspro-newly-diagnosed-light-chain-amyloidosis.

Bochtler T, Hegenbart U, Kunz C, Granzow M, Benner A, Seckinger A, et al. Translocation t(11;14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib-based regimens. J Clin Oncol. 2015;33:1371–8. https://doi.org/10.1200/JCO.2014.57.4947.

Article  PubMed  CAS  Google Scholar 

Kourelis TV, Kumar SK, Gertz MA, Lacy MQ, Buadi FK, Hayman SR, et al. Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosis. J Clin Oncol. 2013;31:4319–24. https://doi.org/10.1200/JCO.2013.50.8499.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Jaccard A, Comenzo RL, Hari P, Hawkins PN, Roussel M, Morel P, et al. Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naive patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III). Haematologica. 2014;99:1479–85. https://doi.org/10.3324/haematol.2014.104109.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Palladini G, Sachchithanantham S, Milani P, Gillmore J, Foli A, Lachmann H, et al. A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis. Blood. 2015;126:612–5. https://doi.org/10.1182/blood-2015-01-620302.

Article  PubMed  CAS  Google Scholar 

Staron A, Zheng L, Doros G, Connors LH, Mendelson LM, Joshi T, et al. Marked progress in AL amyloidosis survival: a 40-year longitudinal natural history study. Blood Cancer J. 2021;11:139. https://doi.org/10.1038/s41408-021-00529-w.

Article  PubMed  PubMed Central  Google Scholar 

Kastritis E, Palladini G, Minnema MC, Wechalekar AD, Jaccard A, Lee HC, et al. Daratumumab-based treatment for immunoglobulin light-chain amyloidosis. N. Engl J Med. 2021;385:46–58. https://doi.org/10.1056/NEJMoa2028631.

Article  PubMed  CAS  Google Scholar 

Comenzo R, Palladini G, Kastritis E, Minnema MC, Wechalekar AD, Jaccard A et al. Subcutaneous daratumumab with bortezomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed light chain (AL) amyloidosis: 18-month analysis of the phase 3 ANDROMEDA Study. Presented at: 2021 ASH Annual Meeting and Exposition; 2021; Atlanta, Georgia. Abstract 159.

Baljevic M. Evolving role of autologous stem cell transplantation for light chain amyloidosis in the modern era. Oncol (Williston Park). 2021;35:474–5. https://doi.org/10.46883/ONC.2021.3508.0474.

Article  Google Scholar 

Manwani R, Cohen O, Sharpley F, Mahmood S, Sachchithanantham S, Foard D, et al. A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib. Blood. 2019;134:2271–80. https://doi.org/10.1182/blood.2019000834.

Article  PubMed  CAS  Google Scholar 

Shen KN, Miao HL, Zhang CL, Feng J, Zhang L, Cao XX, et al. Posttreatment dFLC less than 10 mg/L predicts superior organ response and longer time to next treatment in newly diagnosed light-chain amyloidosis patients treated with bortezomib. Leuk Lymphoma. 2021;62:874–82. https://doi.org/10.1080/10428194.2020.1849675.

Article  PubMed  CAS  Google Scholar 

Sarosiek S, Zheng L, Sloan JM, Quillen K, Brauneis D, Sanchorawala V. Comparing measures of hematologic response after high-dose melphalan and stem cell transplantation in AL amyloidosis. Blood Cancer J. 2020;10:88. https://doi.org/10.1038/s41408-020-00354-7.

Article  PubMed  PubMed Central  Google Scholar 

Godara A, Toskic D, Albanese J, Rosenthal B, Siddiqui NS, Kugelmass A, et al. Involved free light chains <10 mg/L with treatment predict better outcomes in systemic light-chain amyloidosis. Am J Hematol. 2021;96:E20–3. https://doi.org/10.1002/ajh.26025.

Article  PubMed  Google Scholar 

Comenzo RL, Kastritis E, Palladini G, Minnema MC, Wechalekar AD, Jaccard A, et al. Reduction in absolute involved free light chain and difference between involved and uninvolved free light chain is associated with prolonged major organ deterioration progression-free survival in patients with newly diagnosed AL amyloidosis receiving bortezomib, cyclophosphamide, and dexamethasone with or without daratumumab: results from ANDROMEDA. Blood. 2020;136:48–50. https://doi.org/10.1182/blood-2020-137582

Article  Google Scholar 

Palladini G, Paiva B, Wechalekar A, Massa M, Milani P, Lasa M, et al. Minimal residual disease negativity by next-generation flow cytometry is associated with improved organ response in AL amyloidosis. Blood Cancer J. 2021;11:34. https://doi.org/10.1038/s41408-021-00428-0.

Article  PubMed  PubMed Central  Google Scholar